The ELEVATE treatment-naïve study is the first head-to-head comparison of either acalabrutinib or acalabrutinib plus obinutuzumab – two distinct arms – to chlorambucil obinutuzumab, a former standard therapy for CLL. This study is updated from the publication in Lancet which it demonstrated an improved response and improved progression-free survival with both of the experimental arms, acalabrutinib and acalabrutinib plus obinutuzumab as compared to chlorambucil plus obinutuzumab...
The ELEVATE treatment-naïve study is the first head-to-head comparison of either acalabrutinib or acalabrutinib plus obinutuzumab – two distinct arms – to chlorambucil obinutuzumab, a former standard therapy for CLL. This study is updated from the publication in Lancet which it demonstrated an improved response and improved progression-free survival with both of the experimental arms, acalabrutinib and acalabrutinib plus obinutuzumab as compared to chlorambucil plus obinutuzumab.
The data continues showing that the progression-free survival is being sustained with acalabrutinib or acalabrutinib plus obinutuzumab and that the safety profile of this treatment as compared to chlorambucil obinutuzumab is quite favorable. These results continue to demonstrate that a BTK inhibitor with or without a CD20 inhibitor are superior therapies for CLL patients in the treatment-naïve setting.
This study also in the Lancet paper and continuing, although it was a post hoc analysis, demonstrates that there might be advantage in second-generation BTK inhibitors to adding CD20 antibodies to getting deeper remissions that could translate for a subset of patients the opportunity to stop therapy.